Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
Clinical trial NCT06516289 · RECRUITING
Trial details
- NCT number
- NCT06516289
- Sponsor
- Fudan University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-30
- Primary completion
- 2026-06-01
- Enrollment
- 130
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.